It is essential that we continue to investigate ways of protecting the heart following cancer chemotherapy, At present the limited cardioprotective strategies available -- dexrazoxane, ACE-inhibitors, ARB, and beta-blockers -- are not in routine prophylactic use. The gene discussed is ACE; the disease is cancer.